Current Peptide HIV Type-1 Fusion Inhibitors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antiviral Chemistry & Chemotherapy

• Publication date

  2009-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3851/IMP1369PMID 19794228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sifuvirtide, a potent HIV fusion inhibitor peptide.

  2009cited by this paper
• Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil*

  2009cited by this paper
• HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

  2009cited by this paper
• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  2009cited by this paper
• Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

  2008cited by this paper
• Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.

  2008cited by this paper
• Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*

  2008influential reference
• Both lipid environment and pH are critical for determining physiological solution structure of 3‐D‐conserved epitopes of the HIV‐1 gp41‐MPER peptide P1

  2008cited by this paper
• Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides.

  2008cited by this paper
• Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors

  2008cited by this paper
• HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

  2008cited by this paper
• HIV entry inhibitors.

  2007cited by this paper
• HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains

  2007cited by this paper
• Potent D-peptide inhibitors of HIV-1 entry

  2007influential reference
• Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

  2007influential reference
• Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

  2007influential reference
• C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells.

  2007cited by this paper
• HIV entry inhibitors: mechanisms of action and resistance pathways.

  2006cited by this paper
• θ-Defensins Prevent HIV-1 Env-mediated Fusion by Binding gp41 and Blocking 6-Helix Bundle Formation*

  2006cited by this paper
• Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody

  2006cited by this paper
• Structurally Altered Peptides Reveal an Important Role for N-terminal Heptad Repeat Binding and Stability in the Inhibitory Action of HIV-1 Peptide DP178*

  2006cited by this paper
• Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

  2006cited by this paper
• The N-terminal 12 residue long peptide of HIV gp41 is the minimal peptide sufficient to induce significant T-cell-like membrane destabilization in vitro.

  2006cited by this paper
• Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120*

  2005cited by this paper
• Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides

  2005cited by this paper
• Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeutics

  2005cited by this paper
• Efficiency of Interventions in HIV Infection, 1994–2004

  2005cited by this paper
• Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

  2005influential reference
• Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

  2005cited by this paper
• Academic Editor: Andrew Carr, St.

  2005cited by this paper
• A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

  2005cited by this paper
• Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.

  2005cited by this paper
• Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor

  2004cited by this paper
• Inhibition of HIV-1 Envelope Glycoprotein-mediated Cell Fusion by a DL-Amino Acid-containing Fusion Peptide

  2004cited by this paper
• Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides

  2004cited by this paper
• Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir‐Boosted Saquinavir in HIV‐1‐Infected Patients

  2004cited by this paper
• Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment

  2004cited by this paper
• Resistance to enfuvirtide, the first HIV fusion inhibitor.

  2004cited by this paper
• The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.

  2004cited by this paper
• Assessment of Drug‐drug Interaction Potential of Enfuvirtide in Human Immunodeficiency Virus Type 1–infected Patients

  2004cited by this paper
• Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion*

  2003influential reference
• Novel therapies based on mechanisms of HIV-1 cell entry.

  2003cited by this paper
• HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.

  2003cited by this paper
• Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

  2002cited by this paper
• Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.

  2002cited by this paper
• Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41*

  2002cited by this paper
• Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region

  2001influential reference
• Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development

  2001cited by this paper
• N- and C-domains of HIV-1 gp41: mutation, structure and functions.

  2001cited by this paper
• Mode of Action of an Antiviral Peptide from HIV-1

  2001cited by this paper
• Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity*

  2001cited by this paper
• Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry

  2001cited by this paper
• Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein

  2001cited by this paper
• XIII International AIDS Conference

  2000cited by this paper
• Cell biology of virus entry.

  2000cited by this paper
• Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.

  1999cited by this paper
• Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.

  1999influential reference
• Capture of an early fusion-active conformation of HIV-1 gp41

  1998cited by this paper
• HIV entry and its inhibition.

  1998cited by this paper
• The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

  1998cited by this paper
• Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

  1998cited by this paper
• Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors*

  1998cited by this paper
• A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein

  1998cited by this paper
• Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.

  1998cited by this paper
• Core structure of gp41 from the HIV envelope glycoprotein.

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Atomic structure of a thermostable subdomain of HIV-1 gp41.

  1997cited by this paper
• Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects.

  1997cited by this paper
• Fusion Peptides Derived from the HIV Type 1 Glycoprotein 41 Associate within Phospholipid Membranes and Inhibit Cell-Cell Fusion

  1997cited by this paper
• Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.

  1996cited by this paper
• Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion

  1995cited by this paper
• A trimeric structural domain of the HIV-1 transmembrane glycoprotein

  1995influential reference
• The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*)

  1995cited by this paper
• The Inhibitory Activity of an HIV Type 1 Peptide Correlates with Its Ability to Interact with a Leucine Zipper Structure

  1995cited by this paper
• Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

  1994influential reference
• Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

  1993cited by this paper
• Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein

  1993cited by this paper
• Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein

  1993cited by this paper
• Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein.

  1993cited by this paper
• HIV-1 inhibition by a peptide

  1993cited by this paper
• A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

  1992influential reference
• A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

  1992cited by this paper
• The amino-terminal peptide of HIV-1 glycoprotein 41 lyses human erythrocytes and CD4+ lymphocytes.

  1992cited by this paper
• Investigation of Human Immunodeficiency Virus Fusion Peptides. Analysis of Interrelations Between Their Structure and Function

  1992cited by this paper
• Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.

  1990cited by this paper
• Oligopeptide Inhibitors of HIV-Induced Syncytium Formation

  1990cited by this paper
• A General Model for the Transmembrane Proteins of HIV and Other Retroviruses

  1989cited by this paper
• Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa.

  1988cited by this paper
• Lipid composition and fluidity of the human immunodeficiency virus.

  1988cited by this paper
• Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

  1984cited by this paper
• Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

  1983cited by this paper

• An expedient route for the synthesis of an anti-HIV peptide Kn2-7: A TAG approach

  2024cites this paper
• A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

  2024cites this paper
• Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice

  2022cites this paper
• A Review: The Antiviral Activity of Cyclic Peptides

  2022cites this paper
• Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study

  2021cites this paper
• A Focus on Severe Acute Respiratory Syndrome ( SARS ) Coronavirus ( SARS‐CoVs ) 1 and 2

  2021cites this paper
• Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.

  2021cites this paper
• Better understanding and prediction of antiviral peptides through primary and secondary structure feature importance

  2020cites this paper
• Insights of inhibition mechanism of sifuvirtide and MT-sifuvirtide against wild and mutant HIV-1 envelope glycoprotein41: a molecular dynamics simulation and binding free energy study

  2020cites this paper
• SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells

  2020cites this paper
• The Impact of HIV-1 Drug Escape on the Global Treatment Landscape.

  2019cites this paper
• Phosphorylated abacavir analogue (ABC‐1) has ameliorative action against Newcastle disease virus induced pathogenesis in chicken

  2019cites this paper
• Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action

  2019cites this paper
• Pharmaceutical Approaches to HIV Treatment and Prevention

  2018cites this paper
• The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES

  2017cites this paper
• A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading

  2017cites this paper
• Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies

  2017cites this paper
• Antibody engineering for HIV therapeutics : from fusion inhibition to delivery of genetic regulators

  2017cites this paper
• Functional and clinical consequences of immune-driven sequence variation of gag-protease in HIV-1 subtypes A, C, D and recombinants.

  2016cites this paper
• Zwitterionic structures: from physicochemical properties toward computer-aided drug designs.

  2016cites this paper
• In-silico optimization and molecular validation of putative anti-HIV antimicrobial peptides for therapeutic purpose

  2016influential citation
• Using Chou’s Pseudo Amino Acid Composition and Machine LearningMethod to Predict the Antiviral Peptides

  2015cites this paper
• Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.

  2015cites this paper
• An integrated map of HIV genome-wide variation from a population perspective

  2015cites this paper
• Synthesis of anionic carbosilane dendrimers via “click chemistry” and their antiviral properties against HIV

  2014cites this paper
• Co-Expression of Foreign Proteins Tethered to HIV-1 Envelope Glycoprotein on the Cell Surface by Introducing an Intervening Second Membrane-Spanning Domain

  2014influential citation
• Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions

  2014cites this paper
• Investigation of lipodystrophy syndrome in a multicentre prospective cohort of HIV-infected children and adolescents living in Europe

  2013cites this paper
• Analysis and Prediction of Highly Effective Antiviral Peptides Based on Random Forests

  2013cites this paper
• Peptides Corresponding to the Predicted Heptad Repeat 2 Domain of the Feline Coronavirus Spike Protein Are Potent Inhibitors of Viral Infection

  2013cites this paper
• HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

  2013cites this paper
• Use of Retroviral Peptide Libraries for the Identification of Novel Cellular Targets of HIV-1 and the Discovery of Novel Inhibitors

  2012cites this paper
• HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion.

  2012cites this paper
• HIV-Screening Strategies for the Discovery of Novel HIV-Inhibitors

  2011cites this paper
• Hendra and nipah infection: pathology, models and potential therapies.

  2011cites this paper
• DNA Libraries for the Construction of Phage Libraries: Statistical and Structural Requirements and Synthetic Methods

  2011cites this paper
• A Novel Enzyme-Linked Immunosorbent Assay for Screening HIV-1 Fusion Inhibitors Targeting HIV-1 Gp41 Core Structure

  2011cites this paper
• Retrocyclins and their activity against HIV-1

  2011cites this paper
• Inhibition of Influenza Virus Replication by Constrained Peptides Targeting Nucleoprotein

  2011cites this paper
• Susceptibility of HIV-1 Subtypes B′, CRF07_BC and CRF01_AE that Are Predominantly Circulating in China to HIV-1 Entry Inhibitors

  2011cites this paper
• The Post-Antibiotic Era: Promising Developments in the Therapy of Infectious Diseases

  2010cites this paper